Skip to main content

Table 1 Patients’ and tumor characteristics

From: Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus

Parameter Intention to treat Per protocol
Carb/TAX n = 20 CDDP/5FU n = 31 p-value Carb/TAX n = 18 CDDPs/5FU n = 26 p-value
Median Age (IQR) 62 (56–71) 62 (55–72) 0.875 61 (56–69) 65 (57–72) 0.489
Male 13 (65%) 20 (65%) 1.000 13 (72%) 16 (62%) 0.531
T-stage    0.143    0.103
uT1 0 (0%) 1 (3%)   0 (0%) 1 (4%)  
uT2 5 (25%) 2 (6%)   5 (28%) 2 (8%)  
uT3 15 (75%) 27 (87%)   13 (72%) 23 (88%)  
uT4 0 (0%) 1 (3%)   0 (0%) 0 (0%)  
uN+ 20 (100%) 30 (97%) 1.000 18 (100%) 25 (96%) 1.000
cM0 20 (100%) 31 (100%) 1.000 18 (100%) 26 (100%) 1.000
Grading    1.000    0.765
G1 0 (0%) 1 (3%)   0 (0%) 0 (0%)  
G2 11 (58%) 15 (52%)   11 (61%) 14 (56%)  
G3 8 (42%) 13 (45%)   7 (39%) 11 (44%)  
Tumor extension (IQR) 4 (2–6) 5 (3–7) 0.233 4 (2–6) 5 (3–6) 0.232
  1. 5-FU 5-fluoruracil, IQR inter-quartiles-range